Global Iron Deficiency Injectable Market, By Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Others), Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Iron Deficiency Injectable Market Analysis and Size
Iron deficiency injectables also aid in overcoming poor adherence, non-compliance, and adverse gastrointestinal effects of oral medicines. Increasing number of patients undergoing dialysis, growing incidence of elderly population globally, growing expenditure on medications, increasing incidences of iron deficiency anaemia are some of the major factors that are likely to boost the growth of the market. Data Bridge Market Research analyses a growth rate in the iron deficiency injectable market in the forecast period 2023-2030. The expected CAGR of the iron deficiency injectable market tends to be around 9.20% in the mentioned forecast period. The market was valued at USD 11.12 billion in 2022 and would grow to USD 22.5 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Iron Deficiency Injectable Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Others), Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
AbbVie Inc. (U.S.), Covis Pharma GmbH (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Fresenius Kabi AG (Germany), Vifor Pharma Management Ltd.(Switzerland), PHARMACOSMOS A/S (Denmark), Shield Therapeutics plc (U.K.), American Regent, Inc.(U.S.), Rockwell Medical, Inc. (U.S.), Apotex Inc (Canada), Bayer AG (Germany), Akebia Therapeutics, Inc.(U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Aetna Inc. (U.S.), Pfizer Inc (U.S.), Systacare Remedies (India), BSA Pharma Inc. (India)
|
|
Market Opportunities
|
|
Market Definition
Iron deficiency injectables are the drugs which are prescribed for treating iron deficiency and delivered by intravenous (IV) infusion in the body. These IV drugs offer numerous benefits over oral medications by guaranteeing faster absorption of the infused supplements. Iron-deficiency anaemia is a disorder in which the blood does not have enough healthy red blood cells due to the deficiency of iron. For treating these patiets, these injectables are used. It is used only for the treatment of patients who cannot be treated appropriately with oral iron supplements.
Iron Deficiency Injectable Market Dynamics
Drivers
- Increase in Anemia Cases
Anemia is found to be one of the most common blood disorders in the recent times. As per the National Heart, Lung, and Blood Institute, an estimated 3 million individuals suffer from anemia in the U.S. growing incidence of target diseases, such as autoimmune diseases, cancer, rheumatoid arthritis, liver disorders, kidney conditions, thyroid diseases, and inflammatory bowel diseases, is a major factor which is facilitating the growth of the market.
- Prevalence of PCOS
Polycystic ovary syndrome (PCOS) is the the major endocrinopathy among reproductive-aged women, which is not yet perceived as an important health problem in the world. It affects around 4%–20% of women of reproductive age globally. It has been reported that the incidence of PCOS is considered to be more in South Asians than in Caucasians who are residing in the U.K..
Opportunities
- Rising Incidences of Chrinic Diseases
As per the National Kidney Foundation, Inc., the two major causes of chronic kidney disease are diabetes and hypertension. Several survey indicates an estimated 10% of the global population is affected by chronic kidney disease, with more than 2 million individuals receiving dialysis on a regular basis. It is projected that the occurrence of chronic kidney cases will increase across developing economies, such as India and China, that implies an increase in the elderly population in the coming years..
Restraints/Challenges
- Side Effects of Iron Drugs
Common adverse effects of iron drugs include digestive problems such as stomach aches, constipation, nausea, loss of appetite, and vomiting. The huge overdose of oral iron drugs may also include convulsions, shallow or rapid breathing, pale skin, tiredness or weakness, and bluish skin or fingernails.
This iron deficiency injectable market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the iron deficiency injectable market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Iron Deficiency Injectable Market Scope
The iron deficiency injectable market is segmented on the basis of product, application, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Iron Dextran
- Iron Sucrose
- Ferric Carboxymaltose
- Others
Application
- Chronic Kidney Disease
- Inflammatory Bowel Disease
- Cancer
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Iron Deficiency Injectable Market Regional Analysis/Insights
The iron deficiency injectable market is analysed and market size insights and trends are provided by product, application, distribution channel and end-user as referenced above.
The major countries covered in the iron deficiency injectable market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing positive growth for the iron deficiency injectable market throughout the forecasted period due to the surging levels of investment the government for the growth of the biopharmaceutical and biotechnology industry along with development of novel drugs and innovative medical treatment in the region.
North America dominates the market due to rising number of applications in cancer research along with adoption of low cost drugs in clinical diagnostics and development of research laboratories in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Iron Deficiency Injectable Market Share Analysis
The iron deficiency injectable market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to iron deficiency injectable market.
Key players operating in the iron deficiency injectable market include:
- AbbVie Inc. (U.S.)
- Covis Pharma GmbH (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Fresenius Kabi AG (Germany)
- Vifor Pharma Management Ltd.(Switzerland)
- PHARMACOSMOS A/S (Denmark)
- Shield Therapeutics plc (U.K.)
- American Regent, Inc. (U.S.)
- Rockwell Medical, Inc. (U.S.)
- Apotex Inc (Canada)
- Bayer AG (Germany)
- Akebia Therapeutics, Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Aetna Inc.(U.S.)
- Pfizer Inc (U.S.)
- Systacare Remedies (India)
- BSA Pharma Inc. (India)
SKU-